论文部分内容阅读
冠状动脉粥样斑块破裂或蚀损及继发性血栓形成是导致急性心肌梗死(AMl)的主要发病机制。近年来随着ST段抬高型心肌梗死(STEMI)直接经皮冠状动脉介入治疗(PCI)的广泛开展,及多重抗血小板药物的联合治疗,明显降低了AMI患者的死亡率及再梗死率等不良心血管事件。国内外众多研究已证实糖蛋白(GP)Ⅱb/Ⅲa受体拮抗剂的应用可以提供有效的抗血小板作用,减少血栓负荷和继发的远端微循环栓塞,有助于真正恢复冠脉血流和心肌组织水平灌注,使PCI前后获益。
Coronary atherosclerotic plaque rupture or erosion and secondary thrombosis is the leading cause of acute myocardial infarction (AMl) the main pathogenesis. In recent years, with the widespread use of direct percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) and the combination of multiple antiplatelet drugs, the mortality and reinfarction rates in patients with AMI are significantly reduced Adverse cardiovascular events. Numerous studies at home and abroad have demonstrated that the use of glycoprotein (GP) IIb / IIIa receptor antagonists can provide an effective anti-platelet effect, reduce thrombus burden and secondary distal microcirculation embolization, and help to truly restore coronary blood flow And myocardial perfusion, so that before and after PCI benefit.